Search
Filgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigationalRheumatoid arthritis (RA) is a chronic, autoimmune, systemic, and inflammatory disease that causes synovial joint symptoms and can limit range of motion in severe cases. … [A189165] Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.[L16616]
Categories: P-glycoprotein substratesBacillus calmette-guerin substrain russian BCG-I live antigen
go.drugbank.com/drugs/DB16648ApprovedInvestigationalBacillus Calmette-Guerin (BCG) substrain Russian BCG-I is a live BCG vaccine administered directly into the bladder for the adjuvant treatment of papillary urothelial cell carcinoma of the bladder. … Live BCG vaccines administered intravesically have been a gold standard therapy in the adjuvant treatment of non-muscle-invasive bladder cancers for decades,[A232264] used after tumor resection, and are
Difamilast
go.drugbank.com/drugs/DB14987ApprovedInvestigational[L56052, A275420] This skin disease occurs most frequently in children and can have an onset as early as within the first 2 years of life. … The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 2 years of age and older [L55042]. It is approved in Japan and the United States.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InducersEcallantide
go.drugbank.com/drugs/DB05311ApprovedEcallantide is marketed by FDA and EMA under the trade name Kalbitor for subcutaneous injection. … Ecallantide is a potent and selective human plasma kallikrein inhibitor that is indicated for the symptomatic treatment of hereditary angioedema.
Bezlotoxumab
go.drugbank.com/drugs/DB13140Approved[L46976] On November 22, 2016, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of a marketing authorization.
Categories: Antiinfectives for Systemic UseClevidipine
go.drugbank.com/drugs/DB04920ApprovedInvestigationalClevidipine is a dihydropyridine L-type calcium channel blocker that is selective for vascular smooth muscle and is indicated for blood pressure reduction when oral therapy is not an option.
Categories: Antihypertensive Agents Indicated for Hypertension, Cytochrome P-450 SubstratesProducts: Cleviprex 0,5 mg/ml Emulsion zur InjektionTransient receptor potential cation channel subfamily V member 1
go.drugbank.com/bio_entities/BE0001023TargetHumansActs as ionotropic endocannabinoid receptor with central neuromodulatory effects. … Seems to mediate proton influx and may be involved in intracellular acidosis in nociceptive neurons. Involved in mediation of inflammatory pain and hyperalgesia.
Polypeptides: Transient receptor potential cation channel subfamily V member 1Synonyms: Capsaicin receptor, Vanilloid receptor 1Low affinity immunoglobulin gamma Fc region receptor II-a
go.drugbank.com/bio_entities/BE0002098TargetHumansLow affinity receptor. By binding to IgG it initiates cellular responses against pathogens and soluble antigens. Promotes phagocytosis of opsonized antigens
Polypeptides: Low affinity immunoglobulin gamma Fc region receptor II-aSynonyms: IgG Fc receptor II-aTransient receptor potential cation channel subfamily V member 2
go.drugbank.com/bio_entities/BE0009158TargetHumansMay transduce physical stimuli in mast cells (By similarity)
Polypeptides: Transient receptor potential cation channel subfamily V member 2Synonyms: Vanilloid receptor-like protein 1Ankyrin repeat and protein kinase domain-containing protein 1
go.drugbank.com/bio_entities/BE0009411TargetHumansPolypeptides: Ankyrin repeat and protein kinase domain-containing protein 1